{"id":3803,"date":"2025-01-12T03:25:12","date_gmt":"2025-01-12T03:25:12","guid":{"rendered":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/?page_id=3803"},"modified":"2026-04-05T21:09:42","modified_gmt":"2026-04-05T21:09:42","slug":"our-pipeline","status":"publish","type":"page","link":"https:\/\/kodiak-sciences-develop.go-vip.net\/dotcom\/our-pipeline\/","title":{"rendered":"Our Pipeline"},"content":{"rendered":"\n
\"\"<\/span>
\n

GENERATION 2.0<\/h2>\n\n\n\n

Inspired to build the world’s leading high-science retina pipeline<\/p>\n<\/div><\/div>\n\n\n\n\n

OUR PIPELINE<\/h2>\n\n\n\n
\n\n\n\n

Our pipeline is designed to address key limitations of today\u2019s therapies across a broad spectrum of retinal diseases.<\/p>\n\n\n\n

\n
\n
\n
Zenkuda<\/div>\n \n
\n \n
\n
Pre clinical<\/div>\n
Pre IND<\/div>\n
Phase 1\/2<\/div>\n
Phase 3<\/div>\n <\/div>\n \n
\n
BLA<\/div>\n
Commercial<\/div>\n <\/div>\n <\/div>\n

BLA-ready profile in wet AMD, DR and RVO<\/p>

DAYBREAK (wet AMD) enrollment complete<\/p><\/div>\n <\/div>\n

\n
Retinal vascular diseases<\/div>\n
Diabetic retinopathy<\/div>\n
Wet age-related macular degeneration<\/div>\n
Retinal vein occlusion<\/div>\n <\/div>\n<\/div>\n
\n
\n
KSI-501<\/div>\n \n
\n \n
\n
Pre clinical<\/div>\n
Pre IND<\/div>\n
Phase 1\/2<\/div>\n
Phase 3<\/div>\n <\/div>\n \n
\n
BLA<\/div>\n
Commercial<\/div>\n <\/div>\n <\/div>\n

DAYBREAK (wet AMD) enrollment complete<\/p><\/div>\n <\/div>\n

\n
Retinal vascular diseases<\/div>\n
Wet age-related macular degeneration<\/div>\n
Diabetic macular edema<\/div>\n <\/div>\n<\/div>\n
\n
\n
KSI-101<\/div>\n \n
\n \n
\n
Pre clinical<\/div>\n
Pre IND<\/div>\n
Phase 1\/2<\/div>\n
Phase 3<\/div>\n <\/div>\n \n
\n
BLA<\/div>\n
Commercial<\/div>\n <\/div>\n <\/div>\n

PEAK and PINNACLE actively recruiting<\/p><\/div>\n <\/div>\n

\n
Macular edema secondary to inflammation<\/div>\n <\/div>\n<\/div>\n<\/div>\n\n\n\n\n\n\n\n\n\n

OUR CANDIDATES<\/h2>\n\n\n\n
\n\n\n\n

\n
\n
\n
\n \n <\/div>\n
\n

Zenkuda\u2122 (tarcocimab)<\/span>
\n Anti-VEGF\n <\/p>\n <\/div>\n <\/div>\n

\n
\n \n <\/div>\n
\n

KSI-501<\/span>
\n Anti-IL-6, VEGF trap\n <\/p>\n <\/div>\n <\/div>\n

\n
\n \n <\/div>\n
\n

KSI-101<\/span>
\n Anti-IL-6, VEGF trap\n <\/p>\n <\/div>\n <\/div>\n

\n
\n \n <\/div>\n
\n

Multi-mechanistic medicines<\/span>
1 Molecule, Many targets<\/span><\/p>\n <\/div>\n <\/div>\n <\/div>\n

\n
<\/div>\n
<\/div>\n
<\/div>\n
<\/div>\n <\/div>\n<\/div><\/p>\n\n\n

\n
\n
\n
\n
\n \n \n Zenkuda\u2122 (tarcocimab)<\/strong>
\n Anti-VEGF\n <\/span>\n <\/div>\n
\n

An investigational anti-VEGF biologic designed to deliver immediate and durable disease control<\/h2>\n
\n

Zenkuda (tarcocimab tedromer) is our most advanced program, supported by four successful Phase 3 studies.

Zenkuda is an anti-VEGF Antibody Biopolymer Conjugate (ABC\u00ae) being developed to provide strong immediacy and high durability. Across multiple studies in high-prevalence retinal vascular diseases, Zenkuda demonstrated consistent 6-month predominant durability and favorable safety. Designed for flexible 1- to 6-month dosing, Zenkuda has the potential to be a mainstay intravitreal biologic for a broad range of patients.<\/p>\n \n <\/div>\n

\n

Zenkuda combines immediacy and high durability in a single biologic<\/h2>\n
\n

Zenkuda combines unconjugated and ABC\u00ae(conjugated) protein in a single biologic. The unconjugated protein is designed to deliver a strong \u201cpulse\u201d of VEGF inhibition (immediacy) and the conjugated protein is designed to persist in the eye to provide sustained disease control.<\/p>\n \n

\n
\n \n <\/div>\n
\n

Zenkuda and the Science of Durability<\/h3>\n

Zenkuda is an ABC medicine built to last. This designed-in durability is supported by clinical data and is what we call our science of durability.

See the data<\/a><\/p>\n <\/div>\n <\/div>\n\n

Four successful Phase 3 studies across major retinal diseases<\/h2>\n
\n

Primary endpoint met and compelling durability demonstrated.<\/p>\n

\n
\n

GLOW1 Study<\/strong>
Diabetic Retinopathy<\/p>\n <\/div>\n

\n

Study Design<\/strong><\/p>\n